[ad_1]
Hemispherx BioPharma (NYSE: HEB CEO), Thomas Equels, told Proactive Investors that biopharmacy had made significant progress in the study of its flagship drug, Ampligen, for the treatment of ovarian cancer.
Equels presents at the Planet MicroCap Showcase today in Las Vegas. A live broadcast of the presentation can be viewed here:
https: //www.webcaster4.com/Webcast/Pa …
Source link
